Molecular testing in melanoma

Cancer Journal

Volumn 18, Issue 2, 2012, Pages 117-123

  Wilson, Melissa Ann ^a   Nathanson, Katherine L ^b  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

BRAF; copy number; direct sequencing; KIT; Melanoma; molecular testing; next generation sequencing; NRAS; single nucleotide extension; somatic mutation testing

Indexed keywords

B RAF KINASE; G PROTEIN COUPLED RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN GNA11; PROTEIN GNAQ; PROTEIN KIT; PROTEIN NRAS; TYROSINE KINASE RECEPTOR; UNCLASSIFIED DRUG;

CANCER INCIDENCE; CLINICAL DECISION MAKING; GENE MUTATION; GENOMICS; HUMAN; MELANOMA; MOLECULAR BIOLOGY; PATHOGENESIS; PERSONALIZED MEDICINE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SEQUENCE ANALYSIS; SOMATIC MUTATION; TREATMENT PLANNING;

ANIMALS; BIOTECHNOLOGY; CHROMOSOME ABERRATIONS; GENETIC TESTING; HUMANS; MELANOMA; MUTATION; ONCOGENES; SKIN NEOPLASMS;

EID: 84859471285     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: 10.1097/PPO.0b013e31824f11bf     Document Type: Review

References (93)

1. Howlader NA, Krapcho M, Neyman N, et al, eds. SEER Cancer Statistics Review 1975-2008. Bethesda, MD: National Cancer Institute; 2011. Available at: http://seer.cancer.gov/csr/1975-2008/. Accessed on December 1, 2011.
2. Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364:2507-2516.
3. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711-723.
4. Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011; 364:2517-2526.
5. Atkins MB, Lotze MT, Dutcher JP, et al. High-dose recombinant inter-leukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol. 1999;17: 2105-2116. (Pubitemid 29318842)
6. Atkins MB, Kunkel L, Sznol M, et al. High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update. Cancer J Sci Am 6 Suppl. 2000;1:S11-S14.
7. V600-mutant melanoma with low tumor burden at baseline. Presented at the 2011 International Melanoma Congress, Tampa, FL; November 9-13, 2011.
8. Fecher LA, Amaravadi RK, Flaherty KT. The MAPK pathway in melanoma. Curr Opin Oncol. 2008;20:183-189. (Pubitemid 351317406)
9. Ji Z, Flaherty KT, Tsao H. Molecular therapeutic approaches to melanoma. Mol Aspects Med. 2010;31:194-204.
10. Dhomen N, Marais R. BRAF signaling and targeted therapies in melanoma. Hematol Oncol Clin North Am. 2009;23:529-545, ix.
11. Brose MS, Volpe P, Feldman M, et al. BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res. 2002;62:6997-7000. (Pubitemid 35424092)
12. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer [see comment]. Nature. 2002;417:949-954. (Pubitemid 34716871)
13. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417:949-954. (Pubitemid 34716871)
14. Cappuzzo F, Varella-Garcia M, Finocchiaro G, et al. Primary resistance to cetuximab therapy in EGFR FISH-positive colorectal cancer patients. Br J Cancer. 2008;99:83-89. (Pubitemid 351920237)
15. Plesec TP, Hunt JL. KRAS mutation testing in colorectal cancer. Adv Anat Pathol. 2009;16:196-203.
16. Carvajal RD, Antonescu CR, Wolchok JD, et al. KIT as a therapeutic target in metastatic melanoma. JAMA. 2011;305:2327-2334.
17. Kirkwood JM, Bastholt L, Robert C, et al. Phase II, open-label, randomized trial of the MEK 1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma. Clin Cancer Res. 2012;18:555-567.
18. Villanueva J, Vultur A, Lee JT, et al. Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell. 2010; 18:683-695.
19. Marsh S. Pyrosequencing applications. Methods Mol Biol. 2007;373: 15-24.
20. Dufort S, Richard MJ, de Fraipont F. Pyrosequencing method to detect KRAS mutation in formalin-fixed and paraffin-embedded tumor tissues. Anal Biochem. 2009;391:166-168.
21. Thomas RK, Baker AC, Debiasi RM, et al. High-throughput oncogene mutation profiling in human cancer. Nat Genet. 2007;39:347-351. (Pubitemid 46328493)
22. Vasudevan KM, Barbie DA, Davies MA, et al. AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer. Cancer Cell. 2009;16:21-32.
23. Hayden EC. Personalized cancer therapy gets closer. Nature. 2009; 458:131-132.
24. Hurst CD, Zuiverloon TC, Hafner C, et al. A SNaPshot assay for the rapid and simple detection of four common hotspot codon mutations in the PIK3CA gene. BMC Res Notes. 2009;2:66.
25. Ragoussis J, Elvidge GP, Kaur K, et al. Matrix-assisted laser desorption/ionisation, time-of-flight mass spectrometry in genomics research. PLoS Genet. 2006;2:e100.
26. MacConaill LE, Campbell CD, Kehoe SM, et al. Profiling critical cancer gene mutations in clinical tumor samples. PLoS One. 2009;4:e7887.
27. Pepper C, Majid A, Lin TT, et al. Defining the prognosis of early stage chronic lymphocytic leukaemia patients. Br J Haematol. 2012; 156:499-507.
28. Morrissette JJ, Bagg A. Acute myeloid leukemia: conventional cytoge-netics, FISH, and moleculocentric methodologies. Clin Lab Med. 2011; 31:659-686, x.
29. Just PA, Cazes A, Audebourg A, et al. Histologic subtypes, immuno-histochemistry, FISH or molecular screening for the accurate diagnosis of ALK-rearrangement in lung cancer: a comprehensive study of Caucasian non-smokers. [Epub ahead of print December 6, 2011.] Lung Cancer. 2011.
30. Takeda M, Kasai T, Enomoto Y, et al. Genomic gains and losses in malignant mesothelioma demonstrated by FISH analysis of paraffin-embedded tissues. J Clin Pathol. 2012;65:77-82.
31. Senetta R, Paglierani M, Massi D. Fluorescence in-situ hybridization analysis for melanoma diagnosis. [published online ahead of print October 18, 2011] Histopathology.
32. Hossain D, Qian J, Adupe J, et al. Differentiation of melanoma and benign nevi by fluorescence in-situ hybridization. Melanoma Res. 2011; 21:426-430.
33. Weber BL. Cancer genomics. Cancer Cell. 2002;1:37-47. (Pubitemid 41039174)
34. Look AT, Hayes FA, Shuster JJ, et al. Clinical relevance of tumor cell ploidy and N-myc gene amplification in childhood neuroblastoma: a Pediatric Oncology Group study. J Clin Oncol. 1991;9:581-591.
35. Jonsson G, Dahl C, Staaf J, et al. Genomic profiling of malignant melanoma using tiling-resolution arrayCGH. Oncogene. 2007;26:4738-4748. (Pubitemid 47067402)
36. Stark M, Hayward N. Genome-wide loss of heterozygosity and copy number analysis in melanoma using high-density single-nucleotide polymorphism arrays. Cancer Res. 2007;67:2632-2642. (Pubitemid 46548950)
37. Gast A, Scherer D, Chen B, et al. Somatic alterations in the melanoma genome: a high-resolution array-based comparative genomic hybridization study. Genes Chromosomes Cancer. 2010;49:733-745.
38. Greshock J, Feng B, Nogueira C, et al. A comparison of DNA copy number profiling platforms. Cancer Res. 2007;67:10173-10180. (Pubitemid 350070789)
39. Hogervorst FB, Nederlof PM, Gille JJ, et al. Large genomic deletions and duplications in the BRCA1 gene identified by a novel quantitative method. Cancer Res. 2003;63:1449-1453. (Pubitemid 36373627)
40. Schouten JP, McElgunn CJ, Waaijer R, et al. Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification. Nucleic Acids Res. 2002;30:e57.
41. Kozlowski P, Jasinska AJ, Kwiatkowski DJ. New applications and developments in the use of multiplex ligation-dependent probe amplification. Electrophoresis. 2008;29:4627-4636.
42. Palma MD, Domchek SM, Stopfer J, et al. The relative contribution of point mutations and genomic rearrangements in BRCA1 and BRCA2 in high-risk breast cancer families. Cancer Res. 2008;68:7006-7014.
43. Bruno W, Ghiorzo P, Battistuzzi L, et al. Clinical genetic testing for familial melanoma in Italy: a cooperative study. J Am Acad Dermatol. 2009;61:775-782.
44. Stevens-Kroef M, Simons A, Gorissen H, et al. Identification of chromosomal abnormalities relevant to prognosis in chronic lymphocytic leukemia using multiplex ligation-dependent probe amplification. Cancer Genet Cytogenet. 2009;195:97-104.
45. Ross JS, Cronin M. Whole cancer genome sequencing by next-generation methods. Am J Clin Pathol. 2011;136:527-539.
46. Pleasance ED, Cheetham RK, Stephens PJ, et al. A comprehensive catalogue of somatic mutations from a human cancer genome. Nature. 2010;463:191-196.
47. Oettgen P, Finger E, Sun Z, et al. PDEF, a novel prostate epithelium-specific ets transcription factor, interacts with the androgen receptor and activates prostate-specific antigen gene expression. J Biol Chem. 2000;275:1216-1225. (Pubitemid 30051174)
48. Palavalli LH, Prickett TD, Wunderlich JR, et al. Analysis of the matrix metalloproteinase family reveals that MMP8 is often mutated in melanoma. Nat Genet. 2009;41:518-520.
49. Teitz T, Penner M, Eli D, et al. Isolation by polymerase chain reaction of a cDNA whose product partially complements the ultraviolet sensitivity of xeroderma pigmentosum group C cells. Gene. 1990;87: 295-298. (Pubitemid 20146053)
50. Liang C, Feng P, Ku B, et al. Autophagic and tumour suppressor activity of a novel Beclin1-binding protein UVRAG. Nat Cell Biol. 2006; 8:688-699.
51. Wei X, Walia V, Lin JC, et al. Exome sequencing identifies GRIN2A as frequently mutated in melanoma. Nat Genet. 2011;43:442-446
52. van 't Veer LJ, Burgering BM, Versteeg R, et al. N-ras mutations in human cutaneous melanoma from sun-exposed body sites. Mol Cell Biol. 1989;9:3114-3116. (Pubitemid 19163079)
53. Edlundh-Rose E, Egyhazi S, Omholt K, et al. NRAS and BRAF mutations in melanoma tumours in relation to clinical characteristics: a study based on mutation screening by pyrosequencing. Melanoma Res. 2006; 16:471-478. (Pubitemid 44934704)
54. Goel VK, Lazar AJ, Warneke CL, et al. Examination of mutations in BRAF, NRAS, and PTEN in primary cutaneous melanoma. J Invest Dermatol. 2006;126:154-160. (Pubitemid 43336107)
55. Nikolaev SI, Rimoldi D, Iseli C, et al. Exome sequencing identifies recurrent somatic MAP2K1 and MAP2K2 mutations in melanoma. Nat Genet. 2011;44:133-139.
56. Ball NJ, Yohn JJ, Morelli JG, et al. Ras mutations in human melanoma: a marker of malignant progression. J Invest Dermatol. 1994; 102:285-290.
57. Curtin JA, Fridlyand J, Kageshita T, et al. Distinct sets of genetic alterations in melanoma. N Engl J Med. 2005;353:2135-2147. (Pubitemid 41653105)
58. Russo AE, Torrisi E, Bevelacqua Y, et al. Melanoma: molecular path-ogenesis and emerging target therapies [review]. Int J Oncol. 2009; 34:1481-1489.
59. Saldanha G, Potter L, Daforno P, et al. Cutaneous melanoma subtypes show different BRAF and NRAS mutation frequencies. Clin Cancer Res. 2006;12:4499-4505. (Pubitemid 44297798)
60. Lee JH, Choi JW, Kim YS. Frequencies of BRAF and NRAS mutations are different in histological types and sites of origin of cutaneous melanoma: a meta-analysis. Br J Dermatol. 2011;164:776-784.
61. Devitt B, Liu W, Salemi R, et al. Clinical outcome and pathological features associated with NRAS mutation in cutaneous melanoma. Pigment Cell Melanoma Res. 2011;24:666-672.
62. Chin L, Garraway LA, Fisher DE. Malignant melanoma: genetics and therapeutics in the genomic era. Genes Dev. 2006;20:2149-2182.
63. Miller AJ, Mihm MC Jr. Melanoma. N Engl J Med. 2006;355:51-65.
64. Omholt K, Platz A, Kanter L, et al. NRAS and BRAF mutations arise early during melanoma pathogenesis and are preserved throughout tumor progression. Clin Cancer Res. 2003;9:6483-6488. (Pubitemid 38031837)
65. Sebolt-Leopold JS, Herrera R. Targeting the mitogen-activated protein kinase cascade to treat cancer. Nat Rev Cancer. 2004;4:937-947. (Pubitemid 39626217)
66. Long GV, Menzies AM, Nagrial AM, et al. Prognostic and clinicopath-ologic associations of oncogenic BRAF in metastatic melanoma. J Clin Oncol. 2011;29:1239-1246.
67. Greshock J, Nathanson K, Medina A, et al. Distinct patterns of DNA copy number alterations associate with BRAF mutations in melanomas and melanoma-derived cell lines. Genes Chromosomes Cancer. 2009; 48:419-428.
68. Pollock PM, Harper UL, Hansen KS, et al. High frequency of BRAF mutations in nevi. Nat Genet. 2003;33:19-20. (Pubitemid 36068675)
69. Grichnik JM. Kit and melanocyte migration. J Invest Dermatol. 2006; 126:945-947.
70. Curtin JA, Busam K, Pinkel D, et al. Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol. 2006;24:4340-4346. (Pubitemid 46630793)
71. Hemesath TJ, Price ER, Takemoto C, et al. MAP kinase links the transcription factor microphthalmia to c-Kit signalling in melanocytes. Nature. 1998;391:298-301. (Pubitemid 28099019)
72. Lasota J, Miettinen M. Clinical significance of oncogenic KIT and PDGFRA mutations in gastrointestinal stromal tumours. Histopathology. 2008;53:245-266.
73. Sleijfer S, Wiemer E, Seynaeve C, et al. Improved insight into resistance mechanisms to imatinib in gastrointestinal stromal tumors: a basis for novel approaches and individualization of treatment. Oncologist. 2007;12:719-726. (Pubitemid 47036206)
74. Buchdunger E, Cioffi CL, Law N, et al. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther. 2000;295:139-145.
75. Ivan D, Niveiro M, Diwan AH, et al. Analysis of protein tyrosine kinases expression in the melanoma metastases of patients treated with imatinib mesylate (STI571, Gleevec). J Cutan Pathol. 2006;33: 280-285.
76. Kim KB, Eton O, Davis DW, et al. Phase II trial of imatinib mesylate in patients with metastatic melanoma. Br J Cancer. 2008;99:734-740.
77. Hodi FS, Friedlander P, Corless CL, et al. Major response to imatinib mesylate in KIT-mutated melanoma. J Clin Oncol. 2008;26:2046-2051.
78. Lutzky J, Bauer J, Bastian BC. Dose-dependent, complete response to imatinib of a metastatic mucosal melanoma with a K642E KIT mutation. Pigment Cell Melanoma Res. 2008;21:492-493. (Pubitemid 351990966)
79. Guo J, Si L, Kong Y, et al. Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification. J Clin Oncol. 2011;29:2904-2909.
80. Woodman SE, Trent JC, Stemke-Hale K, et al. Activity of dasatinib against L576P KIT mutant melanoma: molecular, cellular, and clinical correlates. Mol Cancer Ther. 2009;8:2079-2085.
81. Wu H, Goel V, Haluska FG. PTEN signaling pathways in melanoma. Oncogene. 2003;22:3113-3122. (Pubitemid 36713763)
82. Stahl JM, Cheung M, Sharma A, et al. Loss of PTEN promotes tumor development in malignant melanoma. Cancer Res. 2003;63: 2881-2890. (Pubitemid 36667160)
83. Tsao H, Mihm MC Jr, Sheehan C. PTEN expression in normal skin, acquired melanocytic nevi, and cutaneous melanoma. J Am Acad Dermatol. 2003;49:865-872. (Pubitemid 37314875)
84. Palmieri G, Capone M, Ascierto ML, et al. Main roads to melanoma. J Transl Med. 2009;7:86.
85. Li J, Yen C, Liaw D, et al. PTEN, a putative protein tyrosine phospha-tase gene mutated in human brain, breast, and prostate cancer. Science. 1997;275:1943-1947. (Pubitemid 27148818)
86. Liaw D, Marsh DJ, Li J, et al. Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nat Genet. 1997;16:64-67. (Pubitemid 27198157)
87. Tsao H, Goel V, Wu H, et al. Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma. J Invest Dermatol. 2004;122:337-341. (Pubitemid 38281053)
88. Mirmohammadsadegh A, Marini A, Nambiar S, et al. Epigenetic silencing of the PTEN gene in melanoma. Cancer Res. 2006;66: 6546-6552. (Pubitemid 44085609)
89. Zhou XP, Gimm O, Hampel H, et al. Epigenetic PTEN silencing in malignant melanomas without PTEN mutation. Am J Pathol. 2000; 157:1123-1128.
90. Singh AD, Bergman L, Seregard S. Uveal melanoma: epidemiologic aspects. Ophthalmol Clin North Am. 2005;18:75-84, viii. (Pubitemid 40348812)
91. Van Raamsdonk CD, Bezrookove V, Green G, et al. Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi. Nature. 2009; 457:599-602.
92. Cruz F 3rd, Rubin BP, Wilson D, et al. Absence of BRAF and NRAS mutations in uveal melanoma. Cancer Res. 2003;63:5761-5766. (Pubitemid 37187472)
93. Van Raamsdonk CD, Griewank KG, Crosby MB, et al. Mutations in GNA11 in uveal melanoma. N Engl J Med. 2010;363:2191-2199.